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phagocytize pathogens. However, even slight perturbations in the 
CNS can induce activation and endocytic damage (Banati et al., 
1993). A post mortem study of a subset of brains donated by par-
ticipants in the Religious Orders Study did not show brain dif-
ferences between NSAID-users and non-users (Arvanitakis et al., 
2008); yet only plaque and tangle burdens were compared, but 
not activated microglia nor other indices of neuroinflammation 
(Mackenzie and Munoz, 1998; Mackenzie, 2000). The results of 
a recent brain imaging study suggest a neuroprotective effect of 
anti-inflammatory drugs on brain volume (Walther et al., 2009). 
Walther et al. (2009) examined gray and white matter volume in 
a group of participants ranging in age from 65 to 93 years who 
were taking NSAIDs or other anti-inflammatory medications. Anti-
inflammatory drugs were associated with widespread attenuated 
age-related volume decline.
In the present study, we extended upon the findings of Walther 
et al. (2009) by examining participants ranging in age from 42 to 
75 years of age, who were NSAID users or non-user controls. Since 
NSAIDs protect against AD and are involved in preservation of 
memory function, we hypothesized that NSAID use would be asso-
ciated with greater volume in brain regions typically affected by 
AD pathology. Analyses were restricted to the hippocampus and 
parahippocampal gray matter, as these regions are known to be pro-
foundly affected in AD (Hyman et al., 1984; de Leon et al., 1989) and 
are also known to be affected by risk factors for AD such as APOE 
ε4 genotype (Trivedi et al., 2006; Burggren et al., 2008; Mueller and 
Weiner, 2009) and parental family history of AD (Johnson et al., 
2006; Mosconi et al., 2007). Based on previous findings indicat-
ing that NSAIDs modify cognitive and brain aging trajectories 
IntroductIon
McGeer et al. (1990) published the remarkable finding that of 
923 arthritis patients older than 64 years, only four had clini-
cal signs of Alzheimer’s disease (AD), a prevalence of only 0.4% 
compared to a prevalence of 5.1% for the general population at 
that time Canadian Study of Health and Aging (1994). Since then, 
additional studies have indicated a protective effect on cognition 
(Hee Kang and Grodstein, 2003; Jonker et al., 2003; Hayden et al., 
2007) and decreased risk for AD with anti-inflammatory drug use 
(McGeer et al., 2006), chiefly non-steroidal anti-inflammatory 
drugs (NSAIDs). Epidemiological evidence for a beneficial effect of 
NSAIDs has been bolstered by the results of animal studies. NSAIDs 
reduce the number of activated microglia and amyloid plaque bur-
den (Lim et al., 2000; Yan et al., 2003; van Groen and Kadish, 2005) 
in amyloid precursor protein (APP) transgenic mouse models of 
AD. Additionally, NSAIDs attenuate inflammation and subsequent 
loss of neurons in models that mimic AD associated inflammation 
via lipopolysaccharide infusion (Willard et al., 2000).
Only a few studies have examined the effect of anti- inflammatory 
drugs on the human brain. NSAIDS appear to decrease microglial 
activation; a comparison of brains from arthritis patients to con-
trol brains at post mortem indicated that NSAID users with senile 
plaques had only one-third of the activated microglia found in 
control brains with senile plaques (Mackenzie and Munoz, 1998). 
A follow-up study by the same investigator found similar results 
and confirmed that the effect was specific to NSAIDs and not ster-
oidal anti-inflammatory medications (Mackenzie, 2000). Microglia 
under normal conditions scavenge the extracellular milieu and tis-
sue to remove debris and endogenous toxic molecules, as well as 
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(Rozzini et al., 1996; Hayden et al., 2007; Walther et al., 2009), we 
tested for an interaction between NSAID use and age on gray matter 
volume. We hypothesized that non-users would exhibit more age-
related brain volume loss compared to the NSAID user group.
MaterIals and Methods
PartIcIPants
Cognitively normal participants from the community recruited as 
part of ongoing studies of brain function and aging were included 
in this study. Prior to participation in these studies, participants were 
screened for eligibility including medical history and MRI scanner 
compatibility. Exclusion criteria were: a diagnosis of dementia, mild 
cognitive impairment, or other cognitive disorder; significant cogni-
tive complaints; prior or current neurological disease or neurosurgery; 
current diagnosis of major Axis I psychiatric disorder; chronic major 
medical conditions (e.g., poorly controlled diabetes or hypertension, 
cardiac disease, cancer treated with radiation or chemotherapy within 
the past 5 years); and a modified Hachinski score (Rosen et al., 1980) 
greater than four. Health history was obtained through a compre-
hensive health and medical history questionnaire as well as screening 
interviews. Cognitive function was tested using a battery of neu-
ropsychological tests administered by experienced technicians. The 
cognitive data were scored independently by the testing technician 
and a second technician. The double-scored results were reviewed 
by a neuropsychologist who resolved any non-clerical discrepancies. 
Participants who scored two standard deviations below the mean on 
any test were excluded from the analysis. Current mood was assessed 
with the Center for Epidemiologic Study-Depression Scale (CES-D) 
and the State-Trait Anxiety Inventory (STAI). Participants showing 
evidence of significant affective dysfunction (CES-D > 16; STAI trait 
scale in > 95th percentile of age- and gender-corrected normative 
data) were excluded. Most participants were administered both the 
STAI and the CES-D, however in a few cases, participants completed 
only one of these tests. The number of participants that underwent 
each test is indicated in Table 1. MRI scans were read by a neuro-
radiologist and were required to be read as normal for inclusion in 
statistical analyses.
Information regarding medication usage was obtained via the 
health and medical history questionnaire. Using this informa-
tion, a total of 25 NSAID users were identified from the original 
pool of subjects (mean age 58.04 ± 7.10 years; mean education 
16.04 ± 1.74 years; 22 women, 3 men). From the remaining pool of 
participants, two non-user controls were identified for every one 
NSAID user, matched for age within 1 year, educational achieve-
ment within 1 year, and sex (mean age 57.60 ± 6.81 years; mean 
education 16.18 ± 2.45 years; 44 women, 6 men). NSAID users were 
defined as individuals who had self-reportedly been taking NSAIDs 
at least once per week for a minimum of 6 months prior to their 
visit. Sixteen of the 25 NSAID users took ibuprofen; six of the 25 
users took one of the following: diclofenac, etodolac, meloxicam, 
nabumetone, piroxicam, rofecoxib; and the remaining three users 
took a combination of NSAIDS: one of the three took naproxen 
and ibuprofen, a second user took rofecoxib and ibuprofen, and 
the third user took rofecoxib and nabumetone. The duration of 
NSAID use ranged from a minimum of 6 months to 16 years. The 
most frequently occurring duration of NSAID was 6 years (modal 
score) prior to MRI scan, with an average of approximately 3 years 
of use prior to scan. Controls were defined as cognitively normal 
individuals who had never reported taking NSAIDS for conditions 
other than occasional headache or minor transient (not chronic) 
pain. All participants gave written informed consent approved by 
the University of Wisconsin Health Sciences Institutional Review 
Board prior to their brain scan and neuropsychological assessment. 
The demographic characteristics of the participants and descriptive 
statistics of the neuropsychological testing are reported in Table 1.
neuroPsychologIcal testIng
Participants underwent neuropsychological evaluation to char-
acterize cognitive function and ensure normal functioning. Test 
results included in this report were common across all participants 
and were: the Rey Auditory Verbal Learning Test (RAVLT), Brief 
Visual Memory Test (BVMT), the Trail Making Test parts A and 
B, CES-D, and STAI.
MagnetIc resonance IMagIng
Magnetic resonance imaging (MRI) scans were obtained using a 
General Electric 3.0 Tesla scanner (Waukesha, WI, USA). A 3D 
T1-weighted image was acquired with an inversion recovery pre-
pared fast gradient echo pulse sequence. Parameters were: inver-
sion time = 600 ms, fast gradient echo read-out with TR/TE/flip 
angle = 9 ms/1.8 ms/20°; acquisition matrix = 256 × 192 × 124, 
interpolated to 256 × 256 × 124; field of view = 240 mm; slice thick-
ness = 1.2 mm (124 slices), no gap; receiver bandwidth = ± 16 kHz; 
acquisition time ∼7.5 min. Other scans were collected but are not 
included here. An experienced neuroradiologist reviewed all images 
prior to the current analysis for clinical evidence of any neurov-
ascular disease or structural abnormality that would exclude the 
subjects from the analysis.
Voxel-based MorPhoMetry (VbM)
T1-weighted images were processed using Statistical Parametric 
Mapping (SPM5) software (http://www.fil.ion.ucl.ac.uk/spm), 
which employs a unified approach for segmentation, combining seg-
mentation of the original anatomical images into gray matter (GM), 
white matter, and cerebrospinal fluid probability images; spatial 
normalization (12-parameter affine transformation and non-linear 
deformation with a warp frequency cutoff of 25) of the segmented 
images to the Montreal Neurological Institute (MNI) template; and 
bias correction, in a single iterative process. The resulting segmented 
images were modulated using the Jacobian values obtained from 
spatial normalization in order to preserve GM volume by scaling 
the final images by the amount of contraction required to warp the 
images to the template. The results from this step were GM volume 
maps for each participant, where the total amount of GM remained 
the same as in the original images. Finally, the normalized maps were 
smoothed using an 8-mm isotropic Gaussian kernel to optimize 
signal to noise and facilitate comparison across participants. Analysis 
of GM volume employed an absolute threshold masking of 0.1 to 
minimize the inclusion of white matter voxels in the analysis.
statIstIcal analysIs
We hypothesized that non-users would show lower GM volume 
compared to NSAID users. Groups were compared using a voxel-
wise two-sample t-test in SPM5. Due to the well-matched sample, 
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we did not include age, education, or gender as  covariates. Total 
GM volume (in mm3) was derived by summing the voxels in 
the modulated, spatially normalized images, and multiplying 
by the voxel volume. GM volume was entered into the model 
as a proportional scaling factor to control for global differ-
ences. Additionally, we examined the effect of age across all 
participants, and in order to test the hypothesis that NSAID 
use would be protective against age-related volume changes, 
we tested for an age by group (NSAID, non-user) interaction 
using a regression model implemented in SPM5. All analyses 
were restricted to hippocampi and parahippocampal gyri bilat-
erally using the Wake Forest University (WFU) Pickatlas and 
Anatomic Automatic labeling atlas (AAL) atlas. An ROI was gen-
erated by combining hippocampi and parahippocampal gyri and 
dilating by two which expanded the ROI by two voxels in each 
direction. Additionally, we masked the effects of group and age 
(main effects) by the interaction effect to exclude regions were the 
group × age interaction results were significant (thresholded at 
p < 0.05). Main effects and the interaction effect were considered 
significant at p < 0.01. A cluster size threshold of 20 contiguous 
voxels was employed in order to exclude clusters of a very small 
size. The Statistical Package for the Social Sciences SPSS version 
16.0 (SPSS, Inc., Chicago, IL, USA) was used for the analysis of 
behavioral data.
results
neuroPsychologIcal characterIzatIon
Performance on the RAVLT, BVMT, and Trail Making Test A did 
not differ significantly between groups. Group means, and results 
of t-tests, are reported in Table 1.
MrI results
Group × age interaction
As shown in Figure 1, there was a significant interaction between 
age and group in bilateral hippocampi (p < 0.01). Increasing age 
in controls was associated with lower volume compared to NSAID 
FIguRe 1 | Age by group interaction. NSAID users showed an attenuated age slope compared to non-user controls in bilateral hippocampi (shown below) and right 
parahippocampal gyrus (not pictured). The results are confined to the study’s a priori regions of interest (hippocampi and parahippocampal gyri). The color bar 
represents the height of the t-statistic.
Table 1 | Demographic, neuropsychological, and gray matter volume 
data.
 NSAID users Controls  p-value
Age, years (SD)  58.04 (7.10) 57.60 (6.81) 0.796
Education, years (SD)  16.04 (1.74) 16.18 (2.45) 0.799
Female, n (%) 22 (88%) 44 (88%) 
Male, n (%) 3 (12%) 6 (12%) 
RAVLT Total, raw (SD)  50.56 (8.03) 52.14 (6.94) 0.381
RAVLT Trial 6, raw (SD) 10.36 (2.48) 10.44 (2.38) 0.893
RAVLT Trial 7, raw (SD) 10.48 (3.16) 10.54 (2.27) 0.925
BVMT Total, raw (SD) 25.92 (6.28) 27.77 (4.71) 0.164
BVMT DR, raw (SD) 10.33 (1.86) 10.54 (1.71) 0.638
Trails A, seconds (SD) 31.76 (13.04) 28.72 (7.95) 0.215
Trails B, seconds (SD) 60.44 (20.39) 62.34 (21.64) 0.716
STAI State, n, raw (SD) 24, 30.21 (10.5) 46, 31.09 (8.51) 0.707
STAI Trait, n, raw (SD) 23, 30.87 (7.12) 48, 29.83 (7.13) 0.568
CESD, n, raw (SD) 24, 6.33 (5.5) 47, 5.72 (7.13) 0.715
Total GM Volume, 0.62 (0.08) 0.64 (0.05) 0.154 
mean (SD)
RAVLT, Rey auditory verbal learning test; BVMT, brief visual memory test; DR, 
delayed recall; STAI, state-trait anxiety inventory; CESD, center for epidemiologic 
study depression scale; GM, gray matter.
users. The greater age-related slope in controls compared to NSAID 
users is plotted in Figure 2. Cluster sizes, MNI coordinates, and 
t values for significant regions are listed in Table 2.
Main effects
Group. Total gray matter volume (in mm3) compared between groups 
using a t-test did not differ significantly between NSAID users and 
non-users, t(73) = 1.44, p = 1.54. A voxel-wise comparison of gray 
matter probability maps between NSAID users and non-users revealed 
a main effect of group in small portions of left bilateral parahippoc-
ampal gray matter, these regions are shown in Figure 3. Cluster sizes, 
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dIscussIon
We performed a voxel-wise analysis of gray matter maps obtained 
in healthy middle to older-age adults and found significant group 
differences in medial temporal lobe. NSAID users showed greater 
volume in bilateral temporal lobe in addition to showing attenu-
ated age-related volume decline compared to non-user controls. 
These results support previous literature indicating a neuroprotec-
tive effect of NSAIDs on the brain (Mackenzie and Munoz, 1998; 
Mackenzie, 2000; Walther et al., 2009).
At present, the mechanisms by which NSAIDs offer neural pro-
tection remain unclear. Recent studies have examined the role 
of NSAIDs in reducing amyloid burden; NSAIDs that appear to 
have an effect on amyloid include ibuprofen, sulindac sulfide, flur-
biprofen, and indomethacin. There may be several mechanisms 
by which this occurs, either via modulation of APP cleavage by 
gamma secretase to favor production of shorter Aβ peptides that 
are less toxic, thus reducing Aβ42, action on BACE via a peroxi-
some proliferator-activated receptor gamma (PPARγ) mediated 
pathway, by direct action on Aβ peptide, or possibly increasing 
amyloid removal by microglia. NSAIDs limit amyloid accumu-
lation in vitro (Blasko et al., 2001; Thomas et al., 2001; Weggen 
et al., 2001), and in transgenic mice (Lim et al., 2000; Heneka 
et al., 2005; McKee et al., 2008). Studies in humans, however, 
have not supported a decrease in AD pathology in NSAID users, 
namely decreased burden of β-amyloid plaques or neurofibrillary 
tangles (Mackenzie and Munoz, 1998; Arvanitakis et al., 2008). 
Surprisingly, no human post mortem studies have examined 
the relationship between neuronal loss and NSAID use. Of the 
characteristics which define AD, it is neuronal loss and synaptic 
pathology – not β-amyloid plaques or neurofibrillary tangles – that 
show the stronger relationship to dementia severity and cognitive 
deficits in AD (DeKosky and Scheff, 1990; Lassmann et al., 1993; 
Gomez-Isla et al., 1997). Although our study only used an indirect 
measure of neuronal loss, namely gray matter volume, our results 
together with a previous report (Walther et al., 2009) support the 
possibility that beneficial effects of NSAIDs are realized through 
neuronal preservation.
The alternative and originally proposed mechanism for ben-
eficial actions of NSAIDs is via reduction in neuroinflammation. 
NSAIDs inhibit cyclooxygenase (COX), which in turn decreases 
production of prostaglandins, hence decreasing the downstream 
inflammatory cascade. It is well established that inflamma-
tion plays a role in AD related neurodegeneration (McGeer and 
McGeer, 1995). In addition to COX-1 and COX-2, a full comple-
ment of inflammatory mediators have been found in the AD brain, 
including c-reactive protein; amyloid P; complement proteins; the 
proinflammatory cytokines interleukin-1, interleukin-6, and tumor 
necrosis  factor-alpha (McGeer and McGeer, 2001). Animal mod-
els of neuroinflammation indicate that lipopolysaccharide (LPS)-
induced inflammation results in a pattern that has many similarities 
to the pattern of disease found in AD. For example, rats infused with 
LPS show an increase in activated microglia in medial temporal 
lobe especially hippocampus, an increase in β-amyloid precursor 
protein production, degeneration of hippocampal CA3 pyramidal 
neurons (Hauss-Wegrzyniak et al., 1998), a loss of pyramidal cells 
in entorhinal cortex (Hauss-Wegrzyniak et al., 2002), loss of basal 
forebrain cholinergic neurons (Willard et al., 2000), decreased 
MNI coordinates, and t values for regions where non-users showed 
less volume compared to NSAID users are listed in Table 2. A contrast 
in the opposite direction (non-users showing greater volume than 
NSAID users) did not show any significant differences.
Age. The main effect of age was examined using voxel-wise regression 
which indicated a significant correlation between age and gray mat-
ter volume. Regions where volume declined with age are shown in 
Figure 4. Cluster sizes, MNI coordinates, and t values for regions where 
older age was associated with smaller volume are shown in Table 2.
Table 2 | MNI coordinates, t-values, and cluster sizes.
 MNI coordinates  
 x y z Peak k (mm3) 
    t value
Age by gRouP INTeRACTIoN
L Hippocampus −18 −25 −10 3.97 601
R Hippocampus 19 −24 −10 3.31 142
R Parahippocampal gyrus 14 −3 −19 2.70 85
gM gRouP DIFFeReNCeS: NSAID > CoNTRolS
R Parahippocampus 21 4 −37 2.94 40
L Parahippocampus −27 −45 −7 2.88 129
L Fusiform −27 −7 −35 2.79 49
L Hippocampus −22 −30 −8 2.76 207
Age eFFeCT
L Hippocampus −20 −20 −16 5.94 3011
L Parahippocampus −32 −38 −5 4.64 1031
R Parahippocampus 26 11 −28 4.90 677
R Parahippocampus 22 −22 −15 4.11 1260
R Hippocampus 12 −35 8 3.64 1062
FIguRe 2 | Age by group interaction plot. Non-users controls showed a 
strong relationship between older age and lower hippocampal volume 
(r = 0.65) compared to the NSAID user group (r = 0.04). Values plotted below 
are from left hippocampus (Y axis) were adjusted for total gray volume.
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loss found in the LPS-only group (Lee et al., 2008). Similarly, rats 
treated with the COX-2 inhibiting NSAID rofecoxib prior to treat-
ment with the excitotoxin N-methyl-d-aspartate, were protected 
against hippocampal neurodegeneration (Hewett et al., 2006).
The protective effect of NSAIDs found in the present study 
may have been mediated via either anti-amyloidogenic or COX-
inhibiting properties; although several observations suggest that 
anti-amyloid effects are less likely. Medial temporal gray matter, 
where a beneficial effect of NSAIDs was found, is not known to 
show high levels of amyloid plaque burden in either normal aging or 
in mild to moderate AD (Arriagada et al., 1992; Rowe et al., 2007), 
and post mortem evaluation of amyloid burden has not been found 
to relate strongly to volume loss (Josephs et al., 2008). Additionally, 
the sample of adults in the present study was cognitively normal and 
the maximum age was 75 years, further decreasing the likelihood 
that amyloid build-up in the non-user control group mediated 
 spatial memory performance (Hauss-Wegrzyniak et al., 2000a), 
and no recovery of memory function over time (Hauss-Wegrzyniak 
et al., 2000b).
Although inflammation in AD is likely secondary to other 
primary pathology (Rogers and Shen, 2000), it is probable that 
neuroinflammation plays a role in neuronal and synaptic damage, 
with several studies indicating that accumulation of inflamma-
tory mediators are neurotoxic (see Glass et al., 2010 for review). 
Cumulative loss of neurons is measurable as atrophy on MRI and 
recently, the increase in a marker of inflammation, interleukin-6, 
was found to correspond with lower regional brain volume in 
rhesus macaque monkeys (Willette et al., 2010) and in middle-
aged humans (Marsland et al., 2008). Conversely, treatment with 
NSAIDs appears to protect against neuronal damage. In an LPS 
model of neuroinflammation, mice pretreated with sulindac sulfide 
3 weeks prior to LPS treatment were protected against the neuronal 
FIguRe 3 | group effect. A voxel-wise comparison of gray matter volume between NSAID users and non-user controls showed small regions of medial temporal 
lobe difference where non-users demonstrated smaller volume, including left hippocampus, and parahippocampal gyrus. The results below are confined by the 
inclusive region of interest mask, and a mask that excludes the significant interaction effect shown in Figure 1. The color bar represents the height of the t-statistic.
FIguRe 4 | Age effect. The regions where older age was associated with lower gray matter volume are shown. The results are confined to the study’s a priori regions 
of interest (hippocampi and parahippocampal gyri) and a mask that excludes the significant interaction effect shown in Figure 1. The color bar represents the height 
of the t-statistic.
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cognition was a criterion for inclusion. Future studies including a 
larger range of cognitive ability may shed more light on the relation-
ship between NSAIDs, brain structure, and cognitive function.
In conclusion, this study, together with previous findings, pro-
vides preliminary support for the notion that NSAIDs exert a ben-
eficial effect on the brain. Beneficial effects manifested as preserved 
volume, and although the study was cross-sectional, the signifi-
cant interaction between group and age point toward attenuated 
volume decline with age, suggesting neuronal protection. Medial 
temporal lobe gray matter volume of NSAID users and controls 
showed increasing difference with greater age, lending support to 
the supposition that intervention should occur in earlier stages, 
perhaps middle age, in order to advance a favorable aging trajec-
tory. At present however, despite the promising epidemiological 
literature, there is no definitive evidence that NSAIDs will protect 
against future cognitive decline and brain disease. Non-selective 
NSAIDs carry a risk of gastrointestinal bleeding (Graham et al., 
2005) and COX-2 inhibitors are now known to carry their own 
health risks. These attributes make NSAIDs less than ideal for a 
long-term prevention trial. Options include short-term prevention 
trials in middle-aged adults that evaluate markers of inflammation 
and CNS pathology via cerebrospinal fluid (CSF) or other mecha-
nisms, rather than waiting for final outcome measures such as con-
version to disease. Longitudinal studies may be used to monitor 
CSF markers together with brain imaging markers that may prove 
to be sensitive to neuroprotection over time. Additionally, further 
work will be needed to evaluate anti-inflammatory therapies or 
regimes that carry less risk than prolonged and intense exposure 
to NSAIDs.
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volume loss. Inhibition of COX with a decrease in downstream 
inflammation is probable, but requires further study using either 
peripheral or central markers of inflammation that can be evaluated 
in conjunction with the imaging data Furthermore, it is important 
to note that even though anti-inflammatory effects are likely, it is 
quite possible that the beneficial effects of NSAIDs are realized 
through multiple mechanisms, including anti-amyloid effects.
Our results confirm previous reports that NSAID users follow a 
different aging trajectory than non-users. The next quandary, then, 
concerns the age boundaries of the critical period where NSAIDs 
exert beneficial effects; when do individuals predisposed to decline 
need intervention? Failed trials in moderate AD (Aisen et al., 2003; 
Reines et al., 2004; de Jong et al., 2008), mild AD (Green et al., 2009), 
and mild cognitive impairment (Thal et al., 2005) indicate that once 
neuropathology has advanced sufficiently to affect cognition, it is 
too late. In fact, it is possible that once pathological processes are 
underway, limiting immune response via NSAIDs may be harmful, 
since microglia perform a role in clearing β-amyloid (Jantzen et al., 
2002; Chakrabarty et al., 2009).
Post mortem data combined with in vivo imaging studies using 
PET and MRI suggest that pathological processes in AD begin sev-
eral years in advance of cognitive decline (Reiman et al., 1996; Braak 
and Braak, 1997; Small et al., 2000; Johnson et al., 2006; Reiman 
et al., 2009; Xu et al., 2009; Bendlin et al., in press). In transgenic 
mouse models of AD, the association of NSAIDs with decreased 
amyloid pathology (Lim et al., 2000) is especially effective when 
initiated at the age of onset of amyloid plaque formation, and less 
so when initiated once pathological processes have progressed (Lim 
et al., 2001). In the Cache county study, epidemiological results 
indicated that NSAIDs need to be commenced before the age 65, 
and that beneficial effects of NSAIDs may be driven by their effect 
on people who are APOE4 positive, a genetic profile which places 
them at greater risk for developing AD (Hayden et al., 2007). Based 
on data showing that brain alterations can be detected in people 
at risk for AD in middle age, it is possible that intervention would 
be prudent even earlier.
There are several limitations to the present study that bear men-
tion. The study included only a small number of NSAID users, and 
the results here will need replication in larger studies. Additionally, 
data on NSAID use was obtained via self-report, and a wide variety 
of NSAIDs were included in the analysis, limiting our interpreta-
tion of the potential mechanisms that underlie the observed effects. 
Studies that combine brain-imaging analysis with medical record 
review of NSAID data usage will be needed to fill this gap. Although 
we found brain differences between the groups, cognitive differ-
ences were not evident. This is perhaps unsurprising, as normal 
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